Octagon Capital Partners

Investor type Micro VC

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 21
Average round size
info
The average size of a deal this fund participated in
$139M
Portfolio companies 18
Rounds per year 0.72
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.14
Exits 7
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Life Science
  • Therapeutics
Summary

Octagon Capital Partners is the famous VC, which was founded in 1993. The fund was located in North America if to be more exact in Canada. The main office of represented VC is situated in the Toronto.

Among the most popular portfolio startups of the fund, we may highlight SinoHub. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Supply Chain Management, Hardware.

The high activity for fund was in 2010. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 1 - 5 millions dollars.

The typical case for the fund is to invest in rounds with 8 participants. The meaningful sponsors for the fund in investment in the same round are Whitebox Advisors, Ramius Capital, Paragon Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Octagon Capital Partners:
Typical Co-investors
Octagon Capital Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Octagon Capital Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AlgoLedge Delray Beach, Florida, United States
Alpha Sigma Capital California, El Segundo, United States
Australian Motoring Services -
CenterState CEO New York, Syracuse, United States
Ecosia Berlin, Berlin, Germany
Probe Capital -
Simpleweb Bristol, England, United Kingdom
SmartSantander Cantabria, Santander, Spain
Standard Oil Ventures Bridgeport, Connecticut, United States
UniQuest, -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Abogen Biosciences

Biotechnology
Life Science
$1B19 Aug 2021 Gusu District, Jiangsu, China

Sonoma BioTherapeutics

Biotechnology
Life Science
Therapeutics
$265M04 Aug 2021 South San Francisco, California, United States

Undercover Snacks

Food and Beverage
Organic Food
$13M21 Jul 2021 East Hanover, New Jersey, United States

Biocytogen

Biotechnology
Health Care
Medical Device
22 Jun 2021 Worcester, Massachusetts, United States

Biopharma
Biotechnology
Clinical Trials
Innovation Management
$80M24 Mar 2021 Xuanwu District, Jiangsu, China

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$160M03 Mar 2021 Philadelphia, Pennsylvania, United States

Cullgen

Biotechnology
Pharmaceutical
$50M25 Feb 2021 Ohio, United States

Vera Therapeutics

Biotechnology
Health Care
$80M19 Jan 2021 South San Francisco, California, United States

Immvira

Clinical Trials
31 Dec 2020 Futian District, Guangdong Province, China
News
Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Octagon Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: